Health Programme DataBase - European Commission

Filter on [TOPICS=Financial contributions to the functioning of non-governmental body (Operating grants)]

3rd Health Programme (2014-2020)

EURORDIS SGA 2016 [EURORDIS SGA 2016]

The EURORDIS Specific Grant Agreement 2016 continues the work of SGA 2015 within the overarching Framework Partnership Agreement 2015-2017. EURORDIS main strategic objectives are to consolidate the Rare Disease patient’s community and strengthen the rare disease patients’ voice; to actively engage rare disease patient representatives to contribute to the adoption, effective implementation and monitoring of relevant EU legislation/strategies and support their integration at national level; to build capacities and empower rare disease patients advocates, members and volunteers;to sustain human, financial and organisational resources. All activities within the SGA 2016 work to this effect.

Start date: 01/01/2016 - End date: 31/12/2016

Keywords : [ Operating Grant ] [ Rare Diseases ] [ Specific Grant Agreement ]

Call: Health Programme Adhoc Call for invited (named) beneficiaries

3rd Health Programme (2014-2020)

EPHA Operating Grant Proposal 2016 SGA [EPHA SGA 2016]

The Annual Work Programme for 2016 of EPHA is drawn from the multiannual work programme 2015-2017 and builds on successes to date. EPHA’s activities in 2016 will continue to contribute to all four objectives of the Third Health Programme. EPHA has formally reviewed our Strategic Plan 2011-2015. We undertook a thorough consultation process involving Board members, Staff and the EPHA membership, and an analysis of EPHA’s operating environment, strengths and weaknesses. The EPHA membership formally approved the new Strategic Plan 2016-2020 at the Annual General Assembly on 4th September 2015. The Work Programme for 2016 reflects the revised strategy to define a clearer selection of priorities. This approach will enable EPHA to manage activities more effectively, encourage closer cooperation between members and across themes, and better monitor and evaluate our impact.EPHA’s overarching strategic objective remains: “To promote good health and wellbeing, to reduce disease and health inequalities in European policies and programmes”. Priorities selected are as follows:Under Aims 1 and 2 of the 3rdHP and EPHA Strategic Objective “Securing a Governance for Health Approach in Key EU Policies” (HiAP):- Agriculture and Food Policy including Alcohol, Tobacco and NCDs- EU Semester for Health- Healthy Trade Policy- Public Health and Research in the EU BudgetUnder Aims 3 and 4 of the 3rdHP and EPHA Strategic Objective “Strengthen EU Policies to Reduce Health Inequalities and Ensure Universal Access to Sustainable, Inclusive Health Systems”:- Universal and Fair Access to Medicines- Action on Antimicrobial Resistance- Inclusive E- and M-Health- HSPAEach of these areas has operational objectives, milestones, deliverables and impact indicators. The Work Programme 2016 also highlights organisational development objectives, particularly on cooperation with academia, communications and financial sustainability, which are priorities for 2016.

Start date: 01/01/2016 - End date: 31/12/2016

Keywords : [ Amr ] [ Anthrax ] [ Anthrax ] [ Blood ] [ Botulism ] [ Breast ] [ Brucellosis ] [ Campylobacteriosis ] [ Cancer ] [ Cardiovascular Diseases ] [ Cervical ] [ Chlamydia ] [ Cholera ] [ Chronic Diseases ] [ Chronic Diseases ] [ Chronic kidney diseases ] [ Chronic pulmonary diseases ] [ Colorectal ] [ Communicable Diseases ] [ Communicable Diseases ] [ Cryptosporidiosis ] [ Dengue fever ] [ Diabetes ] [ Diphtheria ] [ Diseases of zoonotic and environmental origin and vector borne ] [ E ] [ E/M-Health ] [ Echinococcosis ] [ Economic Policy ] [ Emergent pathogens ] [ Epilepsy ] [ Food and waterborne diseases ] [ Giardisasis ] [ Gonorrhea ] [ HIV, STIs & Blood borne infections ] [ Health Research ] [ Healthcare-associated infections ] [ Hepatitis A ] [ Hepatitis B ] [ Hepatitis C ] [ Hiap ] [ Hiv/Aids ] [ Hpv ] [ Hspa ] [ Hspa. ] [ Influenza ] [ Invasive Haemophilus influenzae disease ] [ Invasive pneumococcal disease ] [ Ischaemic heart disease ] [ Legionnaire's diseaese ] [ Leptospirosis ] [ Leptospirosis ] [ Listeriosis ] [ Lung ] [ M-Health ] [ Malaria ] [ Measles ] [ Menongoccal disease ] [ Multiple sclerosis ] [ Mumps ] [ Musculo skeletal conditions ] [ Ncds ] [ Neurological diseases and disorders ] [ Other specific diseases ] [ Parkinson's disease ] [ Participation ] [ Plague ] [ Polio ] [ Prevention ] [ Prevention ] [ Promotion ] [ Protection ] [ Public Health ] [ Qfever ] [ Rabies ] [ Respiratory tract infections ] [ Rubella ] [ SARS ] [ Salmonellosis ] [ Shigellosis ] [ Shigellosis ] [ Smallpox ] [ Stomach ] [ Stroke ] [ Syphilis ] [ Tetanus ] [ Toxoplasmosis ] [ Trade ] [ Trichinellosis ] [ Tuberculosis ] [ Tularaemia ] [ Tularemia ] [ Type I ] [ Typhoid fever ] [ Universal Access ] [ VTEC ] [ Vaccine-preventable diseases ] [ Variant Creutzfeld-Jakob disease ] [ Viral Haemorrhagic fevers ] [ West Nile fever ] [ Yellow fever ] [ Yersiniosis ] [ campylobacteriosis ] [ pertussis ] [ prostate ] [ salmonellosis ] [ skin ] [ type II ]

Call: Health Programme Adhoc Call for invited (named) beneficiaries

3rd Health Programme (2014-2020)

Cancer Leagues Collaborating in Cancer Prevention and Control at the National and European Level [ECL SGA 2016]

The Association of European Cancer Leagues (ECL) is an NGO leading on cancer control actions at the European level since 1980. Represented by members in the EU and non-EU countries at the national level, leagues are often the main resource for the public for cancer control information and services. ECL provides a unique platform for cancer leagues to share specific know-how and experiences and is the only network in existence exclusively for cancer leagues. The running of ECL has been mainly financed by fees from its members, which cover a skeleton staff and office expenses. Prior to receiving co-funding in 2015 in the form of an Operating Grant from the EU, ECL's main source of income was membership fees, rates which have not changed for 10 years, but due to times of austerity, ECL has been unable to justify increasing the fees. ECL applied for an Operating Grant in 2014 to increase its resources in order to be able to implement actions efficiently in line with its renewed strategy 2014-2017. In 2015, the EU co-funding allowed us to increase our activities in the implementation of work for Strategic Goal 2: Promote Cancer Prevention. The grant has enabled ECL to increase our work in cancer prevention, and specifically in communicating the new 4th revision of the European Code Against Cancer in 2015, activities which included confirming translations of the Code, encouraging our members to communicate the Code, targeting young adults and incorporating the messages in all our activities including work at the European Parliament. In 2016 we will continue and expand these efforts with the Code as well as continue our normal and important activities such as tobacco control and patient support, while increasing our work at the national levels with our member leagues and other partners, which will include to a limited extent global partners during the World Cancer Congress in October 2016 in Paris.

Start date: 01/01/2016 - End date: 31/12/2016

Keywords : [ Anorexia ] [ Bulimia ] [ Cancer Control Plans ] [ Cancer Prevention ] [ Cancer Screening ] [ Code Against Cancer ] [ Communication Campaigns ] [ Dietary patterns ] [ Eating disorders ] [ Effectiveness ] [ Food allergies ] [ Food consumption ] [ Health Systems ] [ Hpv ] [ Hpv ] [ Nutrition ] [ Nutrition ] [ Nutritional deficiencies ] [ Obesity ] [ Obesity ] [ Tobacco Control ] [ Vaccination ]

Call: Health Programme Adhoc Call for invited (named) beneficiaries